Cargando…

Advances in immunotherapy modalities for atherosclerosis

Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Qingwen, Liu, Huajiang, Liu, Jinteng, Pang, Yangyang, Liu, Qibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871313/
https://www.ncbi.nlm.nih.gov/pubmed/36703734
http://dx.doi.org/10.3389/fphar.2022.1079185
_version_ 1784877142707798016
author Meng, Qingwen
Liu, Huajiang
Liu, Jinteng
Pang, Yangyang
Liu, Qibing
author_facet Meng, Qingwen
Liu, Huajiang
Liu, Jinteng
Pang, Yangyang
Liu, Qibing
author_sort Meng, Qingwen
collection PubMed
description Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of factors, including endothelial dysfunction, lipid deposits in the artery wall, and monocyte-derived macrophage infiltration, in which both innate immunity and adaptive immunity play an indispensable role. Recent studies have shown that atherosclerosis can be alleviated by inducing a protective immune response through certain auto-antigens or exogenous antigens. Some clinical trials have also demonstrated that atherosclerotic is associated with the presence of immune cells and immune factors in the body. Therefore, immunotherapy is expected to be a new preventive and curative measure for atherosclerosis. In this review, we provide a summary overview of recent progress in the research of immune mechanisms of atherosclerosis and targeted therapeutic pathways.
format Online
Article
Text
id pubmed-9871313
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98713132023-01-25 Advances in immunotherapy modalities for atherosclerosis Meng, Qingwen Liu, Huajiang Liu, Jinteng Pang, Yangyang Liu, Qibing Front Pharmacol Pharmacology Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of factors, including endothelial dysfunction, lipid deposits in the artery wall, and monocyte-derived macrophage infiltration, in which both innate immunity and adaptive immunity play an indispensable role. Recent studies have shown that atherosclerosis can be alleviated by inducing a protective immune response through certain auto-antigens or exogenous antigens. Some clinical trials have also demonstrated that atherosclerotic is associated with the presence of immune cells and immune factors in the body. Therefore, immunotherapy is expected to be a new preventive and curative measure for atherosclerosis. In this review, we provide a summary overview of recent progress in the research of immune mechanisms of atherosclerosis and targeted therapeutic pathways. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871313/ /pubmed/36703734 http://dx.doi.org/10.3389/fphar.2022.1079185 Text en Copyright © 2023 Meng, Liu, Liu, Pang and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Meng, Qingwen
Liu, Huajiang
Liu, Jinteng
Pang, Yangyang
Liu, Qibing
Advances in immunotherapy modalities for atherosclerosis
title Advances in immunotherapy modalities for atherosclerosis
title_full Advances in immunotherapy modalities for atherosclerosis
title_fullStr Advances in immunotherapy modalities for atherosclerosis
title_full_unstemmed Advances in immunotherapy modalities for atherosclerosis
title_short Advances in immunotherapy modalities for atherosclerosis
title_sort advances in immunotherapy modalities for atherosclerosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871313/
https://www.ncbi.nlm.nih.gov/pubmed/36703734
http://dx.doi.org/10.3389/fphar.2022.1079185
work_keys_str_mv AT mengqingwen advancesinimmunotherapymodalitiesforatherosclerosis
AT liuhuajiang advancesinimmunotherapymodalitiesforatherosclerosis
AT liujinteng advancesinimmunotherapymodalitiesforatherosclerosis
AT pangyangyang advancesinimmunotherapymodalitiesforatherosclerosis
AT liuqibing advancesinimmunotherapymodalitiesforatherosclerosis